Integrity Applications, Inc. Stock Other OTC
Equities
IGAP
US45824Q1013
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 5.46M |
---|---|---|---|---|---|
Net income 2022 | -4M | Net income 2023 | -7M | EV / Sales 2022 | - |
Net cash position 2022 | 2.12M | Net cash position 2023 | 4.3M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.92
x | P/E ratio 2023 |
-0.68
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.25% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Goode
CEO | Chief Executive Officer | 56 | 20-12-16 |
James Cardwell
DFI | Director of Finance/CFO | 64 | 23-10-10 |
David Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Drew Sycoff
BRD | Director/Board Member | 57 | 19-07-07 |
Luis J. Malavé
CHM | Chairman | 61 | Feb. 12 |
Director/Board Member | 95 | 09-12-31 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |